Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro-inflammatory cytokines.
The proteasome inhibitor, bortezomib, has anti-myeloma activity even in myeloma cells refractory to multiple prior treatments. Bortezomib blocks the production of nuclear factor-kappaB (NFkappaB)-mediated pro-inflammatory cytokines. We report a patient with myeloma who developed a cutaneous leucoclastic vasculitis (LV) after bortezomib treatment. The patient with LV exhibited a marked increase in serum levels of IL-6, TNF-alpha, and C-reactive protein (CRP). Bortezomib administration may enhance the release of pro-inflammatory cytokines, which might play a role in bortezomib-induced cutaneous LV.
Min
Chang-Ki
CK
Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea. ckmin@catholic.ac.kr
Lee
Seok
S
Kim
Yoo-Jin
YJ
Eom
Ki-Seong
KS
Lee
Jong-Wook
JW
Min
Woo-Sung
WS
Kim
Chun-Choo
CC
Cho
Chul-Soo
CS
Park
Gyeongsin
G
D001897:Boronic Acids / Q000009:adverse effects* / Q000627:therapeutic use; D000069286:Bortezomib; D016207:Cytokines / Q000097:blood; D006801:Humans; D007249:Inflammation / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications* / Q000188:drug therapy; D011719:Pyrazines / Q000009:adverse effects* / Q000627:therapeutic use; D012867:Skin / Q000098:blood supply / Q000473:pathology; D018366:Vasculitis, Leukocytoclastic, Cutaneous / Q000139:chemically induced* / Q000209:etiology
D001897:Boronic Acids; D016207:Cytokines; D011719:Pyrazines; D000069286:Bortezomib